Literature DB >> 22943719

Comparison of laparoscopy and laparotomy in surgical staging of clinical early stage endometrial cancer: a report of early experiences from Turkey.

S Taşkın1, M Güngör, D Öztuna, F Ortaç.   

Abstract

The objective of this study was to assess the feasibility of laparoscopy (LS) in endometrial carcinoma staging. Clinical early stage endometrial cancer patients (n = 153) staged by LS or laparotomy (LT) were compared. A total of 40 (26.1%) patients were treated by LS and 113 (73.9%) by LT. All patients underwent pelvic lymphadenectomy. Lymphadenectomy has been extended to para-aortic space in 55% of the LS group and 70% of the LT group. The majority of patients had stage I-II disease. The median numbers of removed pelvic and para- aortic lymph nodes were similar in two groups (p values 0.213 and 0.199, respectively). Body mass index (BMI) (kg/m(2)) was higher in the LT group (31.2 vs 27.4, p < 0.05). Operation time, age, tumour histology, para-aortic lymphadenectomy and complication rates were similar in the two groups. Four (10%) patients in the LS group and 12 (10.6%) in the LT group had recurrence of disease (p = 1.0). There was no statistical difference for overall survival between the two groups. In conclusion, these findings showed that in endometrial carcinoma cases, laparoscopy has provided adequate staging and similar survival rates with laparotomy.

Entities:  

Mesh:

Year:  2012        PMID: 22943719     DOI: 10.3109/01443615.2012.696156

Source DB:  PubMed          Journal:  J Obstet Gynaecol        ISSN: 0144-3615            Impact factor:   1.246


  2 in total

1.  Surgical Staging of Early Stage Endometrial Cancer: Comparison Between Laparotomy and Laparoscopy.

Authors:  Murat Api; Semra Kayatas; Aysen Telce Boza; Hakan Nazik; Cevdet Adiguzel; Kadir Guzin; Mustafa Eroglu
Journal:  World J Oncol       Date:  2014-01-16

2.  Comparison of Laparoscopy and Laparotomy in Early-Stage Endometrial Cancer: Early Experiences from a Developing Country.

Authors:  Yusuf Cakmak; Duygu Kavak Comert; Isik Sozen; Tufan Oge
Journal:  J Oncol       Date:  2020-04-30       Impact factor: 4.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.